Epic Sciences' revolutionary circulating tumor cell (CTC) detection platform begins with a single, non-invasive blood draw. From this sample, we conduct multiparametric, single cell analysis of protein expression, cell morphology and single cell genomics to see the widest biological range of cells with unmatched sensitivity.
PROCESS: FCP provides a unique, interactive 3D model of the cell population, enabling detailed analysis and identification of cells other technologies might miss.
The key word is functional. In the real world, we see an important difference between what is programmed in the cell through genomics and real function. Most CTC-targeted approaches are prognostic, focusing on simply identifying and enumerating CTCs, providing masses of data but little predictive value. Tumor sequencing, while valuable for specific data, does not provide important insights into clonality or heterogeneity and has limited utility in many indications.
Our enrichment-free, multiparametric approach perceives both genotype and phenotype,
providing us with unique views into disease heterogeneity.
Environment Driven (Lack Of Food)
Environment Driven (AR Inhibition)
Small Cell Phenotype: Loss of
AR & CK, Cell Size Reduction
This unique, proprietary insight enables Epic Sciences tests to deliver the clarity needed to make the most effective therapy decisions – personal, proven and precise.
We can perform single cell genomic profiling of CTCs and pair the genomics to distinct digital pathology features or protein markers expressed allowing us to see both cell phenotype and genotype.
Functional Cell Profiling (FCP) analyzes all nucleated cells within a blood sample at single cell resolution. Cells from a patient’s blood sample are deposited on replicate glass slides and compared for morphological features, biomarker expression and nuclear integrity, using immunoflourescent staining. Guided by cell phenotype and marker expression, CTCs are individually recovered from the slide surface. Their genomes are then amplified (WGA) and analyzed by next-generation sequencing (NGS) for the presence of point mutations, copy number alterations, genome-wide chromosomal instability, ploidy, or genome-wide scarring.
FCP also provides additional capabilities in establishing heterogeneity.
WHOLE GENOME COPY NUMBER VARIATION (CNV)
The FCP platform can characterize CNV and genomic instability in subclonal populations to establish disease heterogeneity, and identify specific oncogene amplification or tumor surpressor deletion, genome-wide.
TARGETED RESEQUENCING ASSAYS
The FCP platform is capable of detecting CTC sub-clonal populations harboring actionable mutations to monitor sensitivity to targeted therapies through the course of treatment. It can also sequence only genes of interest, focusing only on those that are specific drug targets.